Ironwood Pharmaceuticals
IRWD
190 hedge funds and large institutions have $1.55B invested in Ironwood Pharmaceuticals in 2020 Q3 according to their latest regulatory filings, with 24 funds opening new positions, 67 increasing their positions, 65 reducing their positions, and 36 closing their positions.
110% more call options, than puts
Call options by funds: $12.2M | Put options by funds: $5.81M
3% more repeat investments, than reductions
Existing positions increased: 67 | Existing positions reduced: 65
0% more funds holding in top 10
Funds holding in top 10: 2 → 2 (0)
4.3% less ownership
Funds ownership: 111.76% → 107.46% (-4.3%)
6% less funds holding
Funds holding: 202 → 190 (-12)
16% less capital invested
Capital invested by funds: $1.84B → $1.55B (-$293M)
33% less first-time investments, than exits
New positions opened: 24 | Existing positions closed: 36
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Westfield Capital Management
Boston,
Massachusetts
|
+$15M |
| 2 |
BCM
Brown Capital Management
Baltimore,
Maryland
|
+$13M |
| 3 |
Man Group
London,
United Kingdom
|
+$11.5M |
| 4 |
GT
Glenmede Trust
Philadelphia,
Pennsylvania
|
+$8.92M |
| 5 |
BM
Bridger Management
New York
|
+$8.47M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
UBS AM
Chicago,
Illinois
|
-$29.7M |
| 2 |
SPC
Slate Path Capital
New York
|
-$27.2M |
| 3 |
Fidelity Investments
Boston,
Massachusetts
|
-$16.8M |
| 4 |
WP
Woodline Partners
San Francisco,
California
|
-$15.6M |
| 5 |
BNP Paribas Asset Management
Paris,
France
|
-$13.1M |
IRWD Hedge Fund Activity: Q3 2020 in Review
190 of the 4,956 institutional investors tracked by Wall St. Rank reported a position in Ironwood Pharmaceuticals (IRWD) for Q3 2020, worth a combined $1.55B — down 16% from $1.84B a quarter earlier.
Sellers outnumbered buyers: 36 funds closed out of IRWD and 24 opened new positions — a net loss of 12 holders — while 65 trimmed existing stakes and 67 added.
The largest buyer was Westfield Capital Management, adding an estimated $15M. The largest seller was UBS AM, cutting an estimated $29.7M.
- 190 institutional investors held Ironwood Pharmaceuticals (IRWD) as of Q3 2020, down from 202 in Q2 2020.
- Funds reported $1.55B of Ironwood Pharmaceuticals stock for Q3 2020, down 16% quarter-over-quarter.
- 24 funds opened new Ironwood Pharmaceuticals positions in Q3 2020 and 36 closed out, a net change of -12 holders.
- The largest Ironwood Pharmaceuticals buyer in Q3 2020 was Westfield Capital Management, an estimated $15M added.
- The largest Ironwood Pharmaceuticals seller in Q3 2020 was UBS AM, an estimated $29.7M sold.
Based on aggregated 13F filings for Q3 2020.